ZURICH (dpa-AFX Broker) - The major Swiss bank UBS has left its rating for Morphosys at "Buy" with a target price of 47 euros after preliminary figures and an outlook. The forecast for sales of the cancer drug Monjuvi this year is well below market expectations, and she herself had expected more, analyst Xian Deng wrote in a study published on Tuesday. As the Group had already previously provided information on its liquidity requirements, the further targets offered few surprises./tav/ajx

Publication of the original study: 30.01.2024 / 08:39 / GMT

First dissemination of the original study: Date not specified in study / 08:39 / GMT

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------